Outcome by randomly assigned treatment arm. Event-free survival (EFS, top), progression-free survival (PFS, middle), and OS (bottom) from the day of random assignment for all patients undergoing randomization (left) and for the DLBCL subgroup (right). The top 2 curves in each panel represent iPET-negative patients with CD20+ lymphomas, randomly assigned to a total of 6 cycles of R-CHOP with or without 2 additional doses of R. The bottom 2 curves represent iPET-positive patients randomly assigned to a total of 8 cycles of R-CHOP or 2 cycles of R-CHOP followed by 6 blocks of the Burkitt protocol. Baseline stratification factors included age, sex, lymphoma subtype, risk group of the International Prognostic Index, and type of treatment institution.3 The numbers in parentheses represent 95% CIs. No., number; p, log-rank test.
